Keyphrases
Clinical Efficacy
100%
Population-based Study
100%
Myelofibrosis
100%
Ruxolitinib
100%
Hazard Ratio
83%
Overall Survival
33%
Transfusion Requirements
33%
Red Blood Cells
16%
Multivariable
16%
Population-based
16%
Poor Survival
16%
Greedy Algorithm
16%
Platelets
16%
Cox Regression Analysis
16%
Old Age
16%
Survival Benefit
16%
Propensity Score
16%
National Health Insurance Research Database (NHIRD)
16%
Korean National Health Insurance
16%
Blood Platelets
16%
Red Blood Cell Transfusion
16%
Previous History
16%
Delayed Diagnosis
16%
Male Sex
16%
Venous Thrombosis
16%
Platelet Transfusion
16%
Medicine and Dentistry
Myelofibrosis
100%
Ruxolitinib
100%
Hazard Ratio
83%
Overall Survival
33%
Platelet
16%
Erythrocyte
16%
Proportional Hazards Model
16%
Erythrocyte Transfusion
16%
Phlebothrombosis
16%
Thrombocyte Transfusion
16%
Immunology and Microbiology
Hemocyte
100%
Overall Survival
100%
Platelet
100%
Pharmacology, Toxicology and Pharmaceutical Science
Myelofibrosis
100%
Ruxolitinib
100%
Overall Survival
33%
Vein Thrombosis
16%
Biochemistry, Genetics and Molecular Biology
Ruxolitinib
100%
Hemocyte
33%
Overall Survival
33%
Platelet
33%
Phlebothrombosis
16%